Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
Abstract Background/Aims The increasing use of biologic therapies for moderate to severe inflammatory bowel disease (IBD) highlights the importance of optimal treatment sequencing, particularly after vedolizumab (VDZ) exposure. Studies comparing the effectiveness of ustekinumab (UST) and antitumor n...
Saved in:
Main Authors: | Horng-Yih Chiu, Chia-Jung Kuo, Ming-Wei Lai, Ren-Chin Wu, Chien-Ming Chen, Cheng-Tang Chiu, Yu-Bin Pan, Cheng-Hsun Chiu, Puo-Hsien Le |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-12-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-024-03577-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adalimumab induced psoriasis in Crohn’s disease and treatment with ustekinumab: case report and special histopathological findings
by: Fang Qiu, et al.
Published: (2025-01-01) -
Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01) -
Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy
by: A. I. Khavkin, et al.
Published: (2024-01-01) -
Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01) -
Review and External Evaluation of Population Pharmacokinetic Models for Vedolizumab in Patients with Inflammatory Bowel Disease: Assessing Predictive Performance and Clinical Applicability
by: Marija Jovanović, et al.
Published: (2024-12-01)